Search - tctmd.com

Displaying 21 - 40 of 762

Sort: Relevancy | Date

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Caitlin E. Cox

August 29, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Body Fat Distribution Influences Cardiovascular Age

Todd Neale

August 22, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Conference News SCCT 2025

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

Yael L. Maxwell

July 28, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2025

Michael O'Riordan

June 30, 2025

News Daily News

CCTA Bests CV Risk Scores for Bolstering Lifestyle Changes, Medication Uptake

Yael L. Maxwell

June 25, 2025

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

L.A. McKeown

June 12, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

Advertisement

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Evolocumab Gains Expanded Indication for Primary Prevention

Body Fat Distribution Influences Cardiovascular Age

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Less Plaque With Intensive Medical Therapy vs Usual Care in INOCA: WARRIOR

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

TCTMD’s Top 10 Most Popular Stories for June 2025

CCTA Bests CV Risk Scores for Bolstering Lifestyle Changes, Medication Uptake

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content